SubHero Banner
Text

Parsabiv (etelcalcetide) – New drug approval

February 7, 2017 – Amgen announced the FDA approval of Parsabiv (etelcalcetide), for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Download PDF